Geneva Stalls, Washington Signs, Ituri Bleeds: Inside the Quiet Economy of African Outbreaks

On 19 May, a missionary doctor named Peter Stafford was airlifted out of Bunia, in DRC's Ituri Province, on a high-security medical evacuation. His destination: the Charité hospital in Berlin — Europe's most decorated biosafety facility, with a high-security isolation ward that costs more to run for a week than most district hospitals in eastern Congo spend in a year.

Stafford had been infected while caring for patients at Nyankunde Hospital, in a forgotten corner of a forgotten province, with a virus that has no vaccine and no licensed treatment: Bundibugyo, a cousin of Ebola last seen at this scale in 2012. Six high-risk contacts flew with him — some to Germany, some to the Czech Republic — for monitoring in conditions that, frankly, no one in Ituri can offer. The aircraft was equipped with isolation pods. The corridor was cleared. The German interior ministry coordinated.

Stafford — viremic, infectious, irreplaceable — became the most carefully chaperoned person of the week.

Hold that image. It is the perfect metaphor for what is happening to African outbreak biology in 2026.

The pathogen rides first class. The patient stays. The data crosses the ocean. The patent comes later.

Three cities, three speeds

Right now, three things are happening simultaneously, in three different cities, and only one of them is making the headlines.

In Geneva, WHO Member States have just punted the most consequential clause of the Pandemic Agreement — the Pathogen Access and Benefit Sharing (PABS) annex — to 2027. The 79th World Health Assembly closed last week with a polite shrug: "continued engagement," another IGWG session in July, perhaps a special session before year-end, otherwise see you next May. The pharmaceutical industry's official statement at WHA79 lamented that current PABS proposals would "slow and diminish" their work on medicines and vaccines. That is a remarkable sentence. It means: tying us to equity obligations is bad for the equity we promise to deliver.

In Washington, by contrast, things have moved with the speed of a man late for a flight. Between December 2025 and February 2026, the United States signed bilateral health Memorandums of Understanding with sixteen African countries — Kenya, Rwanda, Liberia, Uganda, Lesotho, Eswatini, Mozambique, Cameroon, Nigeria, Madagascar, Sierra Leone, Botswana, Ethiopia, Côte d'Ivoire, Malawi, and Burundi — under the "America First Global Health Strategy." Total committed financing across these deals is north of $14 billion over five years. The deals replace the corpse of USAID with a new arrangement: rapid outbreak reporting, expanded surveillance infrastructure, and — here is the part you have to read twice — direct pathogen-and-data-sharing pipelines to American institutions.

And in Ituri, people are dying. As of the CDC's 24 May situation update, the DRC has logged 626 cases (51 confirmed, 575 suspected) and 148 suspected deaths across Ituri, Nord-Kivu, and Sud-Kivu provinces. Uganda has 12 confirmed cases, several in Kampala. There is no licensed vaccine for the Bundibugyo strain. There is no licensed therapeutic. There are, however, samples. There is sequence data. There is, in clinical terms, the most valuable scientific raw material on the planet — and it is being generated in real time by a beleaguered health system in an active conflict zone, with limited diagnostics and no patent attorneys.

These three cities are not in three different stories. They are in the same one.

The asymmetry hiding in plain sight

The Kenya deal is the only one of the sixteen MOUs that has been made public. We owe that to a single Kenyan senator, Okiya Omtatah, and to the Consumers Federation of Kenya (COFEK), who together took the government to court. On 11 December 2025, the High Court of Kenya issued conservatory orders suspending the data-sharing components of the agreement. It is the most consequential health-data ruling on the continent right now, and almost no one outside Nairobi has heard of it.

Read the public text and you understand why the court pressed pause.

Kenya must detect any infectious disease outbreak with epidemic or pandemic potential within seven days, and notify the United States within one day of detection. Kenya must respond within seven days. Kenya must permit audits of up to five percent of randomly selected health facilities, clinics and laboratories. Kenya must lean on US regulatory approvals as sufficient for medicines used domestically — weakening the autonomy of the Pharmacy and Poisons Board.

In the other direction? Nothing. The United States is not required to notify Kenya of disease outbreaks on American soil. The US is not subject to audit by Kenyan inspectors. Kenya cannot send a team to inspect a CDC facility in Atlanta. There is no symmetric obligation, no symmetric timeline, no symmetric anything.

If a novel hantavirus appears in Vermont — and one will, eventually, because pathogens do not read passports — no one in Washington will be on the phone to Nairobi within twenty-four hours. But when Bundibugyo flared in Ituri, sequence data was on its way to several northern laboratories before WHO had finished writing its first situation report.

This is what experts mean when they talk about asymmetric reciprocity. The polite term is "global cooperation." The honest term is "extraction." Of the sixteen signatory countries, only Kenya has had its agreement subjected to judicial scrutiny. The other fifteen are flying blind.

What only the experts notice

Now, the part most of the press coverage misses.

The real fight inside the PABS negotiations is not about physical samples. It is about Genetic Sequence Data — what insiders call GSD. Twenty-first century vaccine development does not need a vial of blood. It needs a FASTA file. Moderna's COVID-19 vaccine was designed before a single physical sample reached Cambridge, Massachusetts. The sequence was enough. The same is true for the mRNA platforms now being developed against Bundibugyo, Marburg, Lassa, Nipah, and whatever sits next on the WHO Blueprint priority list.

This matters because pharmaceutical industry negotiators have spent two years pushing to keep GSD outside the benefit-sharing obligations of the PABS annex. If sequences flow freely with no strings attached, the entire architecture of "fair and equitable benefit-sharing" collapses into theatre. You do not need a contract to access Ituri's laboratories if a researcher uploads the Bundibugyo genome to GenBank by 6 PM Geneva time. The samples become ceremonial. The sequences are the prize.

Layer onto this a second uncomfortable truth: health data is no longer just health data. It is training material. The AI-driven drug discovery pipelines now being built by Big Pharma and Big Tech — Insitro, Recursion, Isomorphic Labs, and every foundation model with a moat — eat clinical records, genomic data, surveillance reports, and sequence libraries for breakfast. Hand over the data, and you do not just hand over the next vaccine. You hand over the model that will design the vaccine after that, and the diagnostic that will be sold back to your own Ministry of Health at a "preferred partner" rate in 2031.

This is the layer Nicole Spieker named at the WHA, and the layer that the most clear-eyed African analysts have been hammering on for months. Data sovereignty in the age of foundation models is not a privacy concern. It is an industrial policy concern. African states are not negotiating data clauses. They are negotiating the terms of their participation in the next pharmaceutical economy. They are doing so, in most cases, with no model term sheet, no continental legal team, and no clear bottom line.

A third nuance: the Omicron precedent. South African and Botswana scientists identified the variant, sequenced it, and reported it to the world within days. The world's reward was travel bans. Their planes were turned around. Their economies took a hit. Their citizens were profiled at airports. That memory is alive in African policymaking circles, and it shapes how negotiators read every clause that begins with "the recipient country shall promptly share..."

Bundibugyo has no vaccine. But it has many suitors.

Consider what is happening, right now, around the Ituri outbreak — and what would be happening in a parallel universe where PABS had teeth.

In our universe: Bundibugyo virus genome sequences are circulating. Several northern laboratories are racing to assemble candidate antibody cocktails, mRNA constructs, and recombinant vaccine platforms. The first preprints will appear within months. The first patents may already be in early drafting. If a vaccine emerges, it will be branded, priced, and gated. African countries will queue for purchase at whatever price the market — and the bilateral MOU — allows. Some will receive donated doses, often as the outbreak is ending and the supply has gone past its commercial usefulness. This is, almost line for line, what happened in 2014–15 with Ebola Zaire, in 2022 with mpox, and in 2020–21 with COVID. Memory is uneven, but it is not blank.

In a universe with a binding PABS: any product developed using Bundibugyo samples or sequences from this outbreak would carry an enforceable set-aside — a percentage of doses donated, a percentage sold at affordable prices to WHO for distribution in affected regions, with technology-transfer obligations attached. Pharma's preferred number is closer to zero. Africa's preferred number is closer to thirty. The reason PABS is not finalized is that the gap between these positions is the entire game.

Punting to 2027 is not a compromise. It is a victory by inertia for whoever benefits from the status quo. And the status quo is: data goes north, products go to the highest bidder, and the country that bled gets a thank-you letter and an invitation to a panel discussion.

The hantavirus on the side

Quietly, while attention has been on Ebola, another small drama played out earlier this month. The MV Hondius cruise ship outbreak — a multi-country cluster of Andes hantavirus cases linked to a birdwatching stop at Saint Helena — was confirmed and genomically characterized by South Africa's National Institute for Communicable Diseases. NICD did the PCR. NICD did the sequencing. The viral isolate, designated ANDV/Switzerland/Hu-3337/2026, was posted to virological.org by 8 May. Nextstrain phylogenetic pages were set up the same day.

This is excellent African science. It is also structurally free intellectual capital donated to the world. The infrastructure paid for by South African taxpayers generated the sequence that will inform any future Andes virus countermeasure pipeline. None of those countermeasures are likely to be developed in Johannesburg, Cape Town, or Pretoria. None will return revenue to the laboratory that did the foundational work. If a Boston biotech or German university files a patent in 2028 using that sequence in its starting material, the citation will appear in a methods section.

Africa is increasingly good at the science. The science alone is not the prize.

A familiar pattern, in new packaging

If this all feels eerily familiar, it is because the form is older than any of us. Pharmacognosy in the colonies. Bioprospecting in the rainforests. Plant genetic material extracted from Andean farms long before Nagoya. Indigenous knowledge documented, repackaged, trademarked. We named this. We legislated against it. We built international frameworks — the Convention on Biological Diversity, the Nagoya Protocol — to prevent the obvious abuses.

Pathogens were carved out of those frameworks precisely because rapid sharing for public health was deemed too urgent to encumber. PABS was supposed to fill that carve-out with equity terms specific to pandemic response. Two years of negotiation later, PABS is still not signed. The Pandemic Agreement itself cannot be opened for signature until PABS is adopted. Meanwhile, the bilateral pipeline is operationalizing data transfer right now — country by country, five-year horizon, weak disclosure provisions, and audit clauses that face only one direction.

The Akan have a word for this moment: Sankofa. Se wo were fi na wosankofa a yenkyi — it is not wrong to go back for what you have forgotten. We have forgotten how this story usually ends. The pathogen is not the colonizer. The contract is.

What Africa should be asking for — out loud, in chorus

Three things, said simply.

First, make PABS binding, with set-asides that have teeth. A meaningful percentage of pandemic-relevant product output, allocated through WHO, with enforceable timelines and audit rights. No fig-leaf voluntary commitments. If GSD is the new currency of the pharmaceutical economy, GSD must be inside the benefit-sharing perimeter. Anything less is a treaty written in disappearing ink.

Second, publish every bilateral health MOU. Every. Single. One. The Kenyan court did the continent a favor by dragging the document into daylight. Sixteen agreements should not require sixteen court cases. African civil society, parliaments, and the African Union have every right to read what their governments have signed in their name. The Kenya MOU's audit asymmetry was not visible until citizens forced it visible. The same is likely true of the other fifteen.

Third, build a continental data trust before the next outbreak, not after. Africa CDC's Health Security and Sovereignty Agenda is the right address. It needs money, mandate, and political backing to negotiate as a bloc — not as fourteen separate supplicants approaching the same donor in different conference rooms. Diseases do not respect borders. Health sovereignty cannot either.

None of this is anti-cooperation. It is anti-extraction. The distinction matters. Africa needs surveillance, laboratories, vaccines, sequencing capacity, and rapid response. Africa does not need to pay for these by giving away the only strategic asset it has produced through its own suffering: the biological data of its own people, generated in its own outbreaks, by its own scientists, under its own flag.

Coda

Stafford will, if he is fortunate, recover at the Charité. The miners, traders, and nurses of Ituri, who will not be airlifted anywhere, will recover or not depending on what arrives by truck on muddy roads, and on whether the rains hold. Somewhere in a laboratory in Boston or Basel or Heidelberg, a researcher is opening a FASTA file and beginning to design a molecule. None of that researcher's institutional partners has yet signed a binding obligation to share what they build.

Geneva stalls. Washington signs. Ituri bleeds.

Whichever city you wake up in tomorrow, the question is the same:

Who owns the next vaccine — and at what price will it return?

The Daily Pulse is written for those who care enough about Africa to look past the headlines. If this resonated, share it. If it provoked, even better. The conversation about who owns African outbreak data is not going to negotiate itself — and the calendar in Geneva, as we have seen, is in no particular hurry.

About the Author

Dr. Julius Kirimi Sindi is a global expert in research funding, policy impact, and donor relations. With extensive experience in analyzing philanthropy, business, and science funding, Dr. Sindi fosters sustainable and inclusive research ecosystems. He has facilitated international business relationships across Africa, Europe, and Asia. His upcoming book, "The Blueprint of Life Well Lived," explores successful strategies for navigating complex business environments while achieving sustainable growth. He is the author of an upcoming book "How Societies Change and Why Most Reforms Fail," which introduces an African Theory of Scaling rooted in emotional truth, political safety, and system coherence. I hope to publish "CHANGING THE BATTERIES - How to Renew Purpose, Growth, and Connection When Your Light Grows Dim" as soon as possible. He is also the creator of The Daily Pulse, a widely read LinkedIn newsletter offering sharp, human-centered analysis of policy, politics, and development.